A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Interesting Engineering on MSN8d
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
Hosted on MSN10d
FDA Expands Approval of Esketamine for DepressionThe FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Kelsey Warren [email protected] 609 218 4053 Investor contact: Lauren Johnson [email protected] ...
Elon Musk said in a March 2024 interview that he takes ketamine to treat depression. He claimed to have a doctor's prescription for the drug. How often, or under what circumstances, he uses ...
Results and Discussion: The first part of the study demonstrated a decreased level of glutamate receptors in rats exposed to 14 days of RS, following an initial increase observed after 7 days of RS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback